Molbio Diagnostics Limited Q1 FY27 results press release summary

Results press release of 7 Sep 2026, summarised by AI from the filing.

Molbio Q1 FY27 total income ₹411.48 cr, EBITDA ₹103.68 cr and PAT ₹52.74 cr, with growth led by Truenat test-kit consumption.

Key takeaways

1. Guidance No forward guidance given; management says performance should be assessed on a full-year basis due to non-linear revenue profile.
2. Change Export orders of about ₹57 crore pertaining to Q4 FY26 were deferred due to the Gulf situation and recognised in Q1 FY27.
3. Driver Growth led by test-kit consumption across the 12,500+ Truenat devices sold in 90+ countries.
4. Risk Business has a non-linear revenue profile, with performance varying across quarters.

Original filing on BSE

Molbio Diagnostics Limited Q1 FY27 results

As filed: Revenue ₹399 cr, EBITDA ₹91.6 cr, PAT ₹56.6 cr, EBITDA margin 22.9%.

Not scored. No result for the same quarter last year.

Molbio Diagnostics Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (8 Sep 2026), Results deck (8 Sep 2026), Results press release (7 Sep 2026)